153 related articles for article (PubMed ID: 36539400)
41. Immature human dendritic cells enhance their migration through KCa3.1 channel activation.
Crottès D; Félix R; Meley D; Chadet S; Herr F; Audiger C; Soriani O; Vandier C; Roger S; Angoulvant D; Velge-Roussel F
Cell Calcium; 2016 Apr; 59(4):198-207. PubMed ID: 27020659
[TBL] [Abstract][Full Text] [Related]
42. Calcium-activated potassium channel KCa3.1 in lung dendritic cell migration.
Shao Z; Makinde TO; Agrawal DK
Am J Respir Cell Mol Biol; 2011 Nov; 45(5):962-8. PubMed ID: 21493782
[TBL] [Abstract][Full Text] [Related]
43. Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.
Chen CL; Liao JW; Hu OY; Pao LH
Arch Toxicol; 2016 Sep; 90(9):2249-2260. PubMed ID: 26438401
[TBL] [Abstract][Full Text] [Related]
44. KCa3.1: a new player in progressive kidney disease.
Huang C; Pollock CA; Chen XM
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
[TBL] [Abstract][Full Text] [Related]
45. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
46. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration.
Kaushal V; Koeberle PD; Wang Y; Schlichter LC
J Neurosci; 2007 Jan; 27(1):234-44. PubMed ID: 17202491
[TBL] [Abstract][Full Text] [Related]
47. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
48. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Li H; Zhao JL; Zhang YM; Han SX
Clin Exp Hypertens; 2018; 40(4):303-311. PubMed ID: 29388859
[TBL] [Abstract][Full Text] [Related]
49. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
50. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Leanza L; O'Reilly P; Doyle A; Venturini E; Zoratti M; Szegezdi E; Szabo I
Curr Pharm Des; 2014; 20(2):189-200. PubMed ID: 23701546
[TBL] [Abstract][Full Text] [Related]
51. Structure, Gating and Basic Functions of the Ca2+-activated K Channel of Intermediate Conductance.
Sforna L; Megaro A; Pessia M; Franciolini F; Catacuzzeno L
Curr Neuropharmacol; 2018; 16(5):608-617. PubMed ID: 28875832
[TBL] [Abstract][Full Text] [Related]
52. Kca3.1-Related Cellular Signalling Involved in Cancer Proliferation.
Calderón Artavia CG; Arvelo Álvarez FA
Cell Physiol Biochem; 2024 Mar; 58(2):107-127. PubMed ID: 38623063
[TBL] [Abstract][Full Text] [Related]
53. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
54. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells.
Chimote AA; Hajdu P; Kucher V; Boiko N; Kuras Z; Szilagyi O; Yun YH; Conforti L
J Immunol; 2013 Dec; 191(12):6273-80. PubMed ID: 24227782
[TBL] [Abstract][Full Text] [Related]
55. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
56. Calcium-gated K
Tarasov MV; Bystrova MF; Kotova PD; Rogachevskaja OA; Sysoeva VY; Kolesnikov SS
Pflugers Arch; 2017 Feb; 469(2):349-362. PubMed ID: 28028617
[TBL] [Abstract][Full Text] [Related]
57. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells.
Ruggieri P; Mangino G; Fioretti B; Catacuzzeno L; Puca R; Ponti D; Miscusi M; Franciolini F; Ragona G; Calogero A
PLoS One; 2012; 7(10):e47825. PubMed ID: 23110108
[TBL] [Abstract][Full Text] [Related]
58. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
[TBL] [Abstract][Full Text] [Related]
59. Targeting a mitochondrial potassium channel to fight cancer.
Leanza L; Venturini E; Kadow S; Carpinteiro A; Gulbins E; Becker KA
Cell Calcium; 2015 Jul; 58(1):131-8. PubMed ID: 25443654
[TBL] [Abstract][Full Text] [Related]
60. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
